Source:http://linkedlifedata.com/resource/pubmed/id/11249630
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
3
|
| pubmed:dateCreated |
2001-3-15
|
| pubmed:abstractText |
FluMist is an intranasal influenza vaccine, which has been developed by Aviron. The genetically engineered, live, attenuated, cold-adapted virus vaccine produces influenza infection without the symptoms. The product has been field for approval in the US, where Merrill Lynch expects it to be marketed by mid-2000 [336561].
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jun
|
| pubmed:issn |
1464-8431
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
2
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
340-4
|
| pubmed:dateRevised |
2005-11-16
|
| pubmed:meshHeading |
pubmed-meshheading:11249630-Administration, Intranasal,
pubmed-meshheading:11249630-Adult,
pubmed-meshheading:11249630-Animals,
pubmed-meshheading:11249630-Biotechnology,
pubmed-meshheading:11249630-Child,
pubmed-meshheading:11249630-Humans,
pubmed-meshheading:11249630-Influenza Vaccines,
pubmed-meshheading:11249630-Safety,
pubmed-meshheading:11249630-Vaccines, Synthetic
|
| pubmed:year |
2000
|
| pubmed:articleTitle |
Technology evaluation: FluMist, University of Michigan.
|
| pubmed:affiliation |
Novartis Research Institute, Brunner Strasse 59, A-1235, Vienna, Austria. andreas.billich@pharma.novartis.com
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Review,
Clinical Trial, Phase II,
Clinical Trial, Phase III
|